StreetInsider.com News Articles

Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: Stein Jeffrey

Thu, 18 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260618/26666673.html

Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: Stein Jeffrey

Thu, 18 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260618/26666673.html

Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: YARNO WENDY L

Thu, 18 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260618/26666678.html

Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: YARNO WENDY L

Thu, 18 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260618/26666678.html

Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: ROSEN TERRY J

Thu, 18 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260618/26666659.html

Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: ROSEN TERRY J

Thu, 18 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260618/26666659.html

Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: MACKEY CATHERINE J

Thu, 18 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260618/26666641.html

Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: MACKEY CATHERINE J

Thu, 18 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260618/26666641.html

Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: Morrison Scott W

Thu, 18 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260618/26666648.html

Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: Morrison Scott W

Thu, 18 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260618/26666648.html

Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: Hampton Malcolm Garret

Thu, 18 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260618/26666607.html

Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: Hampton Malcolm Garret

Thu, 18 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260618/26666607.html

IDEAYA Biosciences names CEO Yujiro Hata as board chairman

Wed, 17 Jun 2026 06:01:22 -0400

IDEAYA Biosciences (NASDAQ: IDYA) has elected Yujiro S. Hata as Chairman of its Board of Directors, according to a press release. Hata, who founded the South San Francisco-based oncology company, continues in his current role as President and Chief Executive Officer and remains a board member.

Terry Rosen, Ph.D., will serve as Lead Independent Director of IDEAYA's board following the leadership change.

"Since founding IDEAYA over a decade ago, Yujiro's vision, passion for the mission, and leadership have been core to the evolution of IDEAYA from an early science-driven start-up to a leading precision medicine oncology company with an extensive clinical pipeline

IDEAYA Biosciences names CEO Yujiro Hata as board chairman

Wed, 17 Jun 2026 06:01:22 -0400

Terry Rosen, Ph.D., will serve as Lead Independent Director of IDEAYA's board following the leadership change.

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

Wed, 17 Jun 2026 06:00:00 -0400

SOUTH SAN FRANCISCO, Calif., June 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that its Board of Directors has elected Yujiro S. Hata, Chairman of the Board. Mr. Hata is currently President and Chief Executive Officer, and a member of IDEAYA's Board. Terry Rosen, Ph.D., will serve as Lead Independent Director of IDEAYA's Board.

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

Wed, 17 Jun 2026 06:00:00 -0400

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

Wed, 17 Jun 2026 06:00:00 -0400

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

Wed, 17 Jun 2026 06:00:00 -0400

IDEAYA starts phase 1/2 trial of IDE892 for pancreatic, lung cancers

Mon, 15 Jun 2026 06:00:24 -0400

IDEAYA Biosciences Inc. (NASDAQ: IDYA) has enrolled its first patient in a Phase 1 clinical trial evaluating IDE892, an inhibitor of PRMT5, in combination with IDE397, an inhibitor of MAT2A, for MTAP-deleted solid tumors focusing on non-small cell lung cancer and pancreatic cancer.

The South San Francisco-based precision medicine oncology company announced that preclinical studies showed dual inhibition of PRMT5 and MAT2A with the combination resulted in anti-tumor activity in MTAP-deleted tumor models, including complete responses at doses below those required for single-agent activity.

IDE892 demonstrated a CYP3A4 IC50 greater than 45 micromolar and showed no time-dependent inhibition of seven major cytochrome

IDEAYA starts phase 1/2 trial of IDE892 for pancreatic, lung cancers

Mon, 15 Jun 2026 06:00:24 -0400

IDE892 demonstrated a CYP3A4 IC50 greater than 45 micromolar and showed no time-dependent inhibition of seven major cytochrome

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

Mon, 15 Jun 2026 06:00:00 -0400

IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties
IDE892 has a CYP3A4 IC50 greater than 45 micromolar, and did not show time dependent inhibition of any of the 7 major cytochrome P450s (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4) based on full kinetic CYP inactivation assays
IDE892 monotherapy Phase 1 escalation has cleared multiple dose cohorts with maximally efficacious target exposures anticipated at a favorable pill size and the MTD has not yet been reached. IDE892 monotherapy expansion is anticipated in Q3 2026
MTAP-deletion is estimated to occur in up to 40%

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

Mon, 15 Jun 2026 06:00:00 -0400

IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties
IDE892 has a CYP3A4 IC50 greater than 45 micromolar, and did not show time dependent inhibition of any of the 7 major cytochrome P450s (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4) based on full kinetic CYP inactivation assays
IDE892 monotherapy Phase 1 escalation has cleared multiple dose cohorts with maximally efficacious target exposures anticipated at a favorable pill size and the MTD has not yet been reached. IDE892 monotherapy expansion is anticipated in Q3 2026
MTAP-deletion is estimated to occur in up to 40%

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

Mon, 15 Jun 2026 06:00:00 -0400

IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties
IDE892 has a CYP3A4 IC50 greater than 45 micromolar, and did not show time dependent inhibition of any of the 7 major cytochrome P450s (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4) based on full kinetic CYP inactivation assays
IDE892 monotherapy Phase 1 escalation has cleared multiple dose cohorts with maximally efficacious target exposures anticipated at a favorable pill size and the MTD has not yet been reached. IDE892 monotherapy expansion is anticipated in Q3 2026
MTAP-deletion is estimated to occur in up to 40%

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

Mon, 15 Jun 2026 06:00:00 -0400

IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties
IDE892 has a CYP3A4 IC50 greater than 45 micromolar, and did not show time dependent inhibition of any of the 7 major cytochrome P450s (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4) based on full kinetic CYP inactivation assays
IDE892 monotherapy Phase 1 escalation has cleared multiple dose cohorts with maximally efficacious target exposures anticipated at a favorable pill size and the MTD has not yet been reached. IDE892 monotherapy expansion is anticipated in Q3 2026
MTAP-deletion is estimated to occur in up to 40%

Form 8-K IDEAYA Biosciences, Inc. For: Jun 08

Wed, 10 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260610/26629973.html